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Abstract
Magnetometry analysis of brain tissue sub-samples from two neuroferritinopathy patients provides
a preliminary indication that the amount of magnetic iron compounds associated with this rare disease
is significantly larger than in age/sex-matched controls from the same region of the brain. The primary
iron compounds contributing to the remanant magnetization of the tissue above 50 K and at body
temperature, are both blocked and superparamagnetic (SPM) biogenic magnetite (Fe3O4) and/or
maghemite (γ-Fe2O3). The concentration of SPM magnetite is significant and appears to be
proportional to the concentration of ferritin, which varies with progression of the disease. The mutated
ferritin protein appears to be responsible for the presence of iron oxide nano-particules, which in turn
could be responsible for extensive damage in the brain.
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1. Introduction
Neuroferritinopathy (NF) is a rare genetic disorder resulting directly from a known mutation
in the gene encoding for the ferritin light polypeptide. NF has a late onset at ca. 40 years of
age [1], and results in the accumulation of aggregates of ferritin-like clusters and iron in the
basal ganglia and also throughout the brain and is also often associated with a low serum ferritin
level. [2] Magnetic resonance imaging (MRI) is currently used to confirm the location and
amount of iron deposition [2,3] of NF pathology by mapping iron concentrations.
Although a malfunction in the way that ferritin handles iron is at the root of NF, the specific
iron compounds associated with the disease remain unknown [1]. Understanding which iron
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compounds are present is also important for determining the potential mechanisms of neuronal
damage. It is well known that Ferrous (Fe2+) iron can promote free radical damage via the
Fenton reaction. The magnetic iron biomineral magnetite is a mixed-valence iron oxide
providing a potential source of redox-active ferrous iron. In addition, biogenic magnetite may
also generate free radicals via triplet state stabilization due to the strong magnetic fields
associated with it. [4–6]
The study of NF is highly relevant to other diseases, such as Alzheimer’s, Parkinson’s and
Huntington’s diseases. A major feature of virtually all neurodegenerative diseases is the
accumulation of excess iron. This association was first discovered in Alzheimer’s disease more
than 50 years ago [7] and it is thought that iron and other metals promote pathogenesis through
oxidative stress [8–12]. This is particularly important for ferrous iron as its presence can lead
to radical production via the Fenton reaction. However, it is only within the past few years that
advances in the techniques used to study brain iron have started to lead to a better understanding
of the specific iron compounds present and the brain structures with which they are associated
[13–15]. Recently, Smith, Perry and others have begun to make progress in this area using
modified staining techniques [16,17]. They have demonstrated that redox-active iron is closely
associated with AD plaques and neurofibrillary tangles. This work has demonstrated that
lesion-associated iron is distinct from iron sequestered in ferritin and has provided indirect
evidence of the presence of Fe(II) in AD tissue. Other groups have used transmission electron
microscopy and synchrotron x-ray analysis to demonstrate that Fe2+-bearing iron oxides are
associated with pathogenic tissue in AD [14,18,19].
For most of these diseases, however, the underlying pathogenic mechanism is not known. By
examining related neurodegenerative disorders, such as NF - which is well characterized and
arises from a specific genetic defect - we may be able to shed light on the potential role of iron
in the pathogenesis of other, more common conditions. Therefore, in order to characterize and
identify specific iron oxides associated with neuroferritinopathy, we have evaluated the
magnetic properties of brain tissue samples from two NF cases using highly sensitive
Superconducting Quantum Interference Device (SQUID) magnetometry.
2. Materials and methods
Fresh frozen neuroferritinopathy brain tissue samples were obtained from the Newcastle Brain
Tissue Resource at the Institute for Ageing and Health, University of Newcastle. The horse
spleen ferritin was purchased from Biogenisis and was freeze-dried prior to SQUID
magnetometry measurement.
Five brain tissue samples of ca. 0.7g from the basal ganglia, were taken from two
neuroferritinopathy female subjects of ca. 70 years of age. [Given the rarity of
neuroferritinopathy, the exact ages of the patients in this study is not published to preserve
anonymity.] All samples were sub-sectioned with a ceramic knife, stored at −80°C, and
subsequently freeze-dried. Each freeze-dried sub-sample was introduced into a plastic straw
and pressed into a pellet 4 mm high and 5 mm in diameter using a custom-made, non-magnetic
press following procedures developed in our laboratory. [13,20] Control samples were taken
post-mortem from the hippocampus of three females (mean age = 77). Samples were frozen
and measured without tissue fixation.
A change in iron metabolism associated with neurodegenerative diseases is believed to lead to
the formation of iron oxides with distinct magnetic properties [18,19,21,22]. Therefore, the
measurement of the magnetic properties of all samples were characterized using a Quantum
Design MPMS-7 (SQUID) magnetometer. Potential iron contamination has been examined by
our group and the tissues were handled accordingly [23].
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The performed measurements included isothermal remnant magnetization (IRM), a
measurement which probes the ability of a material to retain its magnetization in the absence
of an external field, following step-wise exposure to an increasingly higher fields.
The temperature dependence of magnetization (M vs. T) measured upon warming, after both
cooling the sample in zero field (Zero-field-cooled; ZFC) and in an applied field (Field-cooled;
FC) provides information on the magnetic blocking temperatures for magnetic compounds
within the tissue and may be compared to horse spleen ferritin, which has been well
characterized and is widely used as an analogue for non-pathogenic ferrihydrite/ferritin. [24–
26] A more detailed analysis of the M vs. T measurements, looking at the difference in
magnetization between the FC and the ZFC curve, can also reveal the presence of
superparamagnetic nanoparticles.
Finally, because it has been hypothesized that a mishandling of iron by the ferritin protein may
result in the formation of magnetite under pathogenic conditions related to neurodegeneration
[21,22,27] and because magnetite nano particles have been identified by Quintana et al.[19],
qualitative thermal decay of remanence (TDR) measurements were performed in order to check
for the presence of the Verwey transition. This is a crystallographic transformation leading to
a loss of magnetization upon warming at ca. 120 K which is diagnostic of the presence of
magnetite. [28] Conventionally the decay of the remnant magnetization in TDR measurements
is shown upon warming. For identification purpose and in order to gain in sensitivity, the
measurement was performed upon cooling. The sample was exposed to a magnetic field of 1
T at 170 K, above the Verwey transition, the magnetic field was then quenched, and the
remanent magnetization was measured upon cooling.
3. Results
3.1. IRM curves at 5 and 50 K
IRM measurements at 50 K, shown in Fig. 1, reveal blocked particles which reach their
saturation magnetization at ca. 300 Oe, a typical feature of magnetite (Fe3O4) and/or its
oxidation product maghemite (γ-Fe2O3) with a diameter larger than ca. 13nm [29,30]. The 5
K IRM curves, also shown in Fig. 1, do not reach saturation and highlight the presence of an
antiferromagnetic material [31,32] with magnetization behaviour consistent with ferrihydrite,
the most abundant magnetically ordered iron species in human tissues.
3.2. IRM of HSF at 5 K
Comparison to ferritin standards allows for the quantification of the various magnetic iron-
containing species in the tissue samples. The 5 K IRM curve of HSF shown in Fig. 2 is the
measured curve from which a trivial, blocked magnetite contribution measured at 30 K of ca.
0.01% in mass was subtracted according to the same procedure as the one used below. The
obtained empirical fit of this IRM curve to a second-degree polynomial [2.142 10−5H – 6.407
10−10 H2] is used as a reference in other fits.
3.3. Quantitative analysis of IRM curves
The fit of any IRM curve measured on biological tissue is likely to contain a blocked magnetite
contribution which can be measured at 50 K and empirically fit to a Langevin function (Eq. 1
with the first term only). At 5 K, a non-saturating contribution from ferritin will be modelled
with our standard second-degree polynomial, where only the ferritin fraction is fit. At 5 K, a
third contribution to the remanence arises from magnetite particles ordering magnetically
between 50 and 5 K and this contribution is also empirically fit to a Langevin function which
appears in the second term of Eq. 1. The IRM curves are therefore fit to a three term empirical
expression displayed in Eq. 1,
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IRM5K = f B
MS
2 ( Coth ( μ1HkT ) − kTμ1H ) + f SPM MS2 (Coth( μ2HkT ) − kTμ2H )
+ f ftn (2.142 × 10
−5H − 6.407 × 10−10H 2)
(Eq. 1)
where Ms/2 is the saturation magnetization in emu/g assuming a uniaxial non-interacting
assembly of particles [33], μ1 and μ2 are empirical parameters, and fB fSPM and fFTN are the
respective fractions of blocked magnetite, SPM magnetite and ferritin expressed in g/
gWet Tissue. The first term is fit on its own using the 50 K IRM data and constrained to its value
in the analysis of the 5 K data.
The various contributions are distinct from each other and allow an accurate quantification of
the concentration of ferritin, magnetite that blocks at 50 K, and smaller magnetite particles
which order magnetically between 50 and 5 K. Such detailed analysis was performed on patient
1 fraction1 and patient 2 fraction 1 and the results are reported in Table I. As expected, ferritin
is more abundant by three orders of magnitude. The blocked magnetite level measured in
neuroferritinopathy tissue is between 57 and 128 ng/gWet Tissue (96 ± 32), higher than is
normally measured in age/sex matched freeze-dried control tissues from the same region of
the brain (12–27 ng/gWet Tissue ), as reported in Table I. The concentration of SPM magnetite
particles appears to vary with the concentration of ferritin which, in turn, varies with the
evolution of the disease. SPM magnetite concentrations were of the order of 50 to 100 ng/g,
bringing the total amount of magnetite in the tissue to 100–200 ng/g.
3.4. SPM particles
Additional evidence of the presence of these SPM magnetite particles is given in the field
cooled and zero-field cooled results measured in 200 Oe and is shown in Fig. 3. The shape of
the FC and ZFC curve in Fig. 3 is similar to those observed in horse spleen ferritin[24–26] but
the difference between the FC and ZFC curves is significantly different. For ferritin, this
difference decreases sharply from 5 to 25 K and is trivial at higher temperatures. [24–26] The
difference between the FC and ZFC curve exhibit a rapid decrease of the magnetization between
5 and 25K which is characteristic of ferritin. In order to remove any ferritin contribution from
the magnetisazation shown in the inset of Fig. 3, the difference curve of FC-ZFC was plotted
between 25 and 300 K. The observed non-trivial magnetization is compatible with SPM or
blocked magnetite with a coercivity larger than 200 Oe, thereby reinforcing conclusions drawn
from the IRM measurements.
3.5. Identification of magnetite
The field at which the remnant magnetization saturates suggests the presence of magnetite/
maghemite. The observation of a strong Verwey transition [28] at ca. 125 K in the TDR
measurement of one of the two samples reported shown in Fig. 4 confirms that at least part of
the measured magnetization in that sample is due to magnetite. Measurement on the other
samples were a lot noisier and inconclusive because of a low signal. Maghemite, a ferric iron
oxide with magnetic properties similar to magnetite, is generally formed via the oxidation of
ferrous iron in magnetite and could be responsible for a possible absence of the Verwey
transition in some of the samples.
4. Discussion
While some of the magnetic measurement techniques employed here cannot unequivocally
identify magnetite, the magnetization data is completely consistent with this iron oxide or its
oxidation product, maghemite. In addition, the presence of the Verwey transition measured in
one of the two samples is clearly indicative of magnetite. Therefore, the preliminary results
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reported here indicate that in Neuroferritinopathy, the malfunction of the ferritin light
polypeptide appears to lead to the formation of SPM magnetite. The presence of magnetite
may reduce the bioavailability of iron, and potentiate free radical production via the Fenton
reaction and/or triplet state stabilization [4–6]. The characterization of intermediate magnetic
iron compounds associated with the mineral bio-transformation of iron, which can lead to the
formation of magnetite, in neurodegenerative disorders such as Neuroferritinopathy and others
can be performed by SQUID magnetometry[13,24–26] and nuclear magnetic resonance[15,
34]. Using such knowledge, it may be possible to develop new pulse sequences for MRI-based
early diagnosis. This is particularly important for diseases such as Alzheimer’s, where
treatments in development are aimed primarily at slowing or halting progression of the disease
rather than reversing its effects. In this case, diagnosis and intervention at the earliest possible
stage should lead to better treatment outcomes.
The coercivity data presented here, as well as TEM imaging conducted on magnetic extracts
from hippocampal tissue [6,21], indicate that larger, blocked magnetite particles are present
within the tissue as well. The origin of these remains unknown but they may grow from
nucleation sites within ferritin followed by a breakdown of the protein shell. While in situ TEM
analysis would help to clarify this conundrum, the low concentration of blocked magnetite in
the tissue (on the order of –ng/g of wet tissue) means that finding them in tissue sections is not
a trivial exercise. This is the main reason for the recent development of automated scanning
techniques which employ micro-focused synchroton x-ray analysis [15,35].
Recent electron microscopy analysis of ferritin from Alzheimer’s tissue indicates that cubic,
mixed-valence iron oxides may be forming within the protein related to pathogenesis [19,36].
This provides an indication that neuroferritinopathy may be a good model system for studying
the effects of disruptions in ferritin function in other neurodegenerative diseases.
Although large crystals of biogenic magnetite have previously been observed [21] in the human
brain, the origin of such large crystals remains unknown.
The presence of SPM magnetite in AD brain tissues has previously been reported and appears
to originate from the biomineralization of the ferrihydrite core of Ferritin as a possible pathway
for the formation of larger magnetite particles. [13,14,18–22] In this study, the presence of
SPM magnetite is correlated with the amount of ferrihydrite suggesting that a malfunction of
ferritin may play a role in the magnetite biomineralization process. Because of the rarity of the
disease and the paucity of available data these results should be considered as preliminary at
this stage.
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Fig 1.
The isothermal remanence of magnetization and their empirical fit to eq. 1, for sample 1 fraction
1 at 5 K (■) and 50 K (●), and for sample 2 fraction 1 at 5 K (□) and 50 K (○).
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Fig 2.
IRM curve of HSF measured at 5 K and fit to a second-degree polynomial: 2.142 10−5H –
6.407 10−10 H2.
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Fig 3.
Temperature dependence of the magnetization of patient 1 fraction 1, measured in zero-field
cooled and field cooled conditions with a field of 200 Oe. The inset shows the difference
between the two curves above 25 K where there is no contribution from ferritin.
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Fig 4.
The thermal decay of remanence measured on patient 2 fraction 2, through the Verwey
transition, in zero-field, and upon cooling; after having applied a field of 1 Tesla.
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Table I
IRM measurements at 1 T of neuroferritinopathy samples
Patient - Fraction IRMsat,50K, μemu/g(WT) [MagnBl],
ng/g(WT)
[MagnSPM],
ng/g(WT)
[Ferritin],
μg/g(WT)
[Ferritin]/
[MagnSPM]
50K 150K 300K
1-1 6.3* 1.9 - 128[4]* 96[9]* 286[7]* 2.98*
1-2 - 2.8 - 57[3] - - -
1-3 - 3.4 - 69[17] - - -
2-1 5.0* 2.6 - 102[4]* 44[14]* 132[6]* 3.00*
2-2 - 6.1 - 124[21] - - -
- - 0.6 12 - - -
Controls - - 0.6 12 - - -
- - 1.3 27 - - -
*
numbers based on an empirical fit of an IRM curve rather than a measurement at saturation. The error is based on an instrumental error for single point
measurements and on the variance of the refined parameter for sample 1-1 and 2-1.
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